Protein tyrosine phosphatase 1β (PTP1β) acts as a negative regulator of insulin signaling. Selective inhibition of PTP1β has served as a potential drug target for the treatment of type 2 diabetes mellitus. We evaluated the inhibitory effect of Phellinus linteus against PTP1β as part of our ongoing search for natural therapeutic and preventive agents for diabetes mellitus. Fractions of the P. linteus extract were found to exhibit significant inhibitory activities against PTP1β. In an attempt to identify bioactive components, we isolated, from the most active ethyl acetate fraction, five hispidin derivatives (phelligridimer A, davallialactone, hypholomine B, interfungins A, and inoscavin A) and four phenolic compounds (protocatechuic acid, protocatechualdehyde, caffeic acid, and ellagic acid). The chemical structures of these compounds were elucidated from spectroscopic evidence and by comparison with published data. All the compounds strongly inhibited PTP1β activity in an in vitro assay; their IC 50 values ranged from 9.0 ± 0.01 to 58.2 ± 0.3 µM. Our results indicated that the hispidin skeleton may be an important moiety for inhibitory activity of the above compounds against PTP1β. Thus, hispidin derivatives could be a potent new class of natural PTP1β inhibitors.
Protein tyrosine phosphatases (PTPs) are a group of enzymes that remove phosphate groups from phosphorylated tyrosine residues on proteins. Together with tyrosine kinases, PTPs regulate the phosphorylation state of many important signaling molecules, such as members of the MAP kinase family. Among them, protein tyrosine phosphatase 1β (PTP1β) plays a critical role in the signal transduction of both the insulin and leptin pathway [1, 2] . This role has been demonstrated for the dephosphorylated insulin receptor and other proteins in intact cells and thus, PTP1β can act as a negative regulator of the insulin signaling pathway [3] . Also, the deletion of the PTP1β gene in mice has been reported to induce marked insulin sensitivity and prolonged the autophosphorylation of the insulin receptor [4] . PTP-1β inhibitors would increase insulin sensitivity by blocking the PTP1β-mediated negative regulation of the insulin signaling pathway [5] . Therefore, PTP1B has emerged as a novel target for the treatment of diabetes and obesity, with numerous compounds having been developed as PTP1β inhibitors [6] . Small molecule inhibitors of PTP-1β, such as oxalamides, benzoic acid, and phenoxyacetic acids were reported [7] . Of them, only ertiprotafib progressed to clinical trials prior to discontinuation at phase II due to insufficient efficacy, coupled with unwanted side effects [8] . Although several types of PTP1β inhibitors have been reported, they have low selectivity and poor pharmacokinetic properties; therefore, new types of PTP1β inhibitors with improved pharmacological properties are still being sought.
Phellinus linteus (Berkeley & M. A. Curtis)
, an orange colored mushroom in the family Hymenochaetaceae, has been used in oriental countries for centuries to prevent ailments such as gastrointestinal dysfunction, diarrhea, hemorrhage, inflammation, and cancer [9] . Although they produce a large and diverse variety of secondary metabolites, polysaccharides have been considered to be responsible for their biological effect. β-Glucans derived from P. linteus act as an effective immunomodulator, exhibit a wide range of antitumor activity and have been shown to prevent metastasis [10] . Also, polysaccharide of P. linteus has been reported to be effective for diabetes in non-obese diabetic mouse [11] .
A recent investigation of the chemical constituents of the genera Inonotus and Phellinus resulted in isolation of hispidin derivatives with a novel carbon skeleton, such as phellifuropyranone A [12] , phellinusfurans A and B [13] , phellinone [14] , phellinsin A [15] , inoscavins A-D and methylinoscavin A-D [16, 17] , phelligridins A-G [18] [19] [20] and interfungins A-C [21] . However, there have been few studies on the biological activities of these compounds. In our recent study, hispidin derivatives from P. linteus exerted potent antioxidant effects, as well as marked inhibitory effects on rat lens aldose reductase and advanced glycation end product formation, corresponding to high values of total phenolic content and total flavonoid content [22, 23] .
While screening for PTP1β inhibitors from natural resources, the MeOH extract of the fruiting body of P. linteus was found to inhibit PTP1β activity at a concentration of 16.3 μg/mL; this led us to investigate the PTP1β inhibitory components from this plant. In this paper, we report the isolation and structural elucidation of active principles with an inhibitory activity against PTP1β.
To identify the active principles, we performed bioassay-guided fractionation and purification by using repeated column chromatography, which resulted in 5 hispidin derivatives and 4 phenolic compounds ( Figure 1 ). The isolated compounds were identified by analysis of their NMR and MS data as phelligridimer A (1), davallialactone (2), hypholomine B (3), interfungin A (4) and inoscavin A (5), as well as hispidin (6), protocatechuic acid (7), protocatechualdehyde (8), caffeic acid (9), and ellagic acid (10) data were compared with those found in the literature [24] [25] [26] [27] . The inhibitory activities of the isolated compounds against PTP1β were measured using p-nitrophenyl phosphate (pNPP) as the substrate; the results are summarized in Table 2 . The known PTP1β inhibitor, ursolic acid (IC 50 = 3.9 ± 0.3 μM), was used as a positive control. The isolated compounds 1-10 dose-dependently inhibited the PTP1β activity with IC 50 values ranging from 9.0 ± 0.6 to 58.2 ± 3.4 μM.
The hispidin derivatives 1-6 were found to show greater inhibitory activities against PTP1β than the phenolic compounds 7-10. Of the hispidin derivatives, compounds 1 and 3 with a hispidin moiety exhibited a greater inhibitory activity against PTP1β than compounds 2, 4, and 5, which have a hispolon moiety. As shown in Table 2 , the inhibitory effects of the hispidin derivatives were enhanced when a hispidin dimer or tetramer was formed. Among the hispidin derivatives, compound 1, a hispidin tetramer, exhibited the highest inhibitory activity against PTP1β with an IC 50 of 8.9 ± 0.6 μM. This result indicates that compound 1 is approximately 2-to 3-fold more effective than other hispidin derivatives. Compounds 1-6 are highly oxygenated and functionalized aromatic compounds that possess the unique basic structural unit, namely, 6-[2-(3,4-dihydroxyphenyl)ethenyl]-4hydroxy-2H-pyran-2-one (hispidin, 6). It has been reported that compound 3, which has an unusual structure with 2,3-dihydro-4-H-furo[3,2-c]pyran-4-one, may be biosynthesized by oxidative coupling of two hispidin mediates, while compound 1 may be sequentially or simultaneously formed by oxidative coupling of four hispidin mediates and/or by oxidative coupling of two hypholomine B molecules [24] .
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Natural Product Communications Vol. 5 (12) 2010 1929 Compounds 2 and 5 are known to be biosynthesized by rearrangement of compound 4, which is biosynthesized by the condensation of hispidin and 6-(3,4-dihydroxyphenyl)-4-hydroxy-3,5-hexadiene-2-one (hispolon) [21] . This suggests that a dihydrofuro[3,2c]pyran-4-one moiety is formed by a cyclization linkage between the A and B rings via an oxygen-bridge that might increase the inhibitory activity against PTP1β. Phelligridins H and I have an unprecedented carbon skeleton (pyrano-[4,3-c]isochromen-4-one) as the structural element. A previous study reported inhibitory activity of these 2 derivatives from P. igniarius against PTP1β [20] . Although the structure-activity relationships of the hispidin derivatives were not thoroughly investigated, the dihydrofuro[3,2-c]pyran-4-one moiety appeared to correlate with the inhibitory activity against PTP1β. The hispolon moiety might be responsible for a loss of PTP1β activity. Thus, the inhibitory activities of the hispidin derivatives might provide valuable information regarding the structure -activity relationship for the development of novel PTP1β inhibitors.
Experimental

Plant materials:
The fresh fruiting bodies of P. linteus were provided by Samsung Herb Medicine Co., Ltd., Chuncheon, Korea and the voucher specimen (No. RIC-021) was deposited at the Regional Innovation Center, Hallym University, Republic of Korea. 1 H and 13 C NMR spectra were recorded on a Bruker DPX 400 spectrometer. Sephadex LH 20 (GE Healthcare Bio-Science AB, Sweden) and cosmosil 75C18-OPN (Nacalai tesque, Kyoto, Japan) were used as column packing material. PTP1β (human, recombinant) drug discovery kit was purchased from BIOMOL ® International Inc. (USA).
Chemicals and equipment:
Isolation and identification:
The lyophilized fruiting bodies of P. linteus (1 kg) were extracted 3 times with MeOH for 5 h. After removal of MeOH under reduced pressure, a dark brown residue (50 g, 5%) was obtained. This was suspended in water and then partitioned sequentially with n-hexane (8 g, 0.8%), methylene chloride (4.9 g, 0.5%), ethylacetate (EtOAc, 22 g, 2.2%), n-butanol (14.1 g, 1.4%), and water (1 g, 0.1%). Sequential fractionation indicated that the EtOAcsoluble fraction showed PTP1β inhibitory activity. Therefore, this fraction was chromatographed over Sephadex LH 20 eluting with MeOH. Among the 8 pools (Fr.1-Fr.8), combined by their HPLC profiles, Fr. 7 was found to have the highest activity. Mixed frs. 5, 7, and 8 was subjected to Lichroprep® RP-18 CC using a stepwise gradient of AcCN-H 2 O (1:4 to 4.5:5.5) to afford compounds 1-6. Fractions 1-3 were each purified by reversed phase HPLC using an isocratic solvent system of 15% AcCN to isolate compounds 7-9, respectively. Compound 10 was obtained as crude crystals from Fr. 4, which was further purified by HPLC using an isocratic solvent system of 20% AcCN. The structures of 1-10 were identified by comparison of observed spectroscopic data with published values.
Assay for PTP1β inhibitory activity:
The PTP 1β tyrosine phosphatase drug discovery kit is a colorimetric, non-radioactive assay designed to measure the phosphatase activity of purified PTP1β [28] . The enzyme activity was measured by using IR5 phosphopeptide (Insulin Receptor B residues 1142-1153, pY-114) as a substrate. To each 96-well (final volume: 125 μL) was added 75 μM IR5 substrate and PTP1β (2.5 ng/well) in a buffer containing 100 mM MES (pH 6.0), 0.3 M NaCl, 2 mM EDTA, 2 mM dithiothreitol (DTT) and 0.1% NP-40 with or without test compounds. Following incubation at 37°C for 30 min, the reaction was terminated with BIOMOL RED TM reagent. The amount of produced p-nitrophenol was estimated by measuring the absorbance at 620 nm. The non-enzymatic hydrolysis of IR5 substrate was corrected by measuring the increase in absorbance at 620 nm obtained in the absence of PTP1β enzyme.
